Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 18;15(16):4171.
doi: 10.3390/cancers15164171.

Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia

Daisuke Tomizawa  1 , Shin-Ichi Tsujimoto  2
Affiliations
Review

Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia

Daisuke Tomizawa et al. Cancers (Basel). .

Abstract

Acute Myeloid Leukemia (AML) is the second most common type of leukemia in children. Recent advances in high-resolution genomic profiling techniques have uncovered the mutational landscape of pediatric AML as distinct from adult AML. Overall survival rates of children with AML have dramatically improved in the past 40 years, currently reaching 70% to 80% in developed countries. This was accomplished by the intensification of conventional chemotherapy, improvement in risk stratification using leukemia-specific cytogenetics/molecular genetics and measurable residual disease, appropriate use of allogeneic hematopoietic stem cell transplantation, and improvement in supportive care. However, the principle therapeutic approach for pediatric AML has not changed substantially for decades and improvement in event-free survival is rather modest. Further refinements in risk stratification and the introduction of emerging novel therapies to contemporary therapy, through international collaboration, would be key solutions for further improvements in outcomes.

Keywords: acute myeloid leukemia; chemotherapy; children; cytogenetics; hematopoietic stem cell transplantation; measurable residual disease; molecular genetics; novel therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Genetic profiles of pediatric AML. Data is from the JPLSG AML-05 study. * Percentage of the patients with FLT3-ITD per total patients (e.g., patients with RUNX1::RUNX1T1 and FLT3-ITD accounts for 0.8% of all 369 cases).
Figure 2
Figure 2
Induction therapy used in pediatric AML.
See this image and copyright information in PMC

References

    1. Creutzig U., van den Heuvel-Eibrink M.M., Gibson B., Dworzak M.N., Adachi S., de Bont E., Harbott J., Hasle H., Johnston D., Kinoshita A., et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood. 2012;120:3187–3205. doi: 10.1182/blood-2012-03-362608. - DOI - PubMed
    1. Khoury J.D., Solary E., Abla O., Akkari Y., Alaggio R., Apperley J.F., Bejar R., Berti E., Busque L., Chan J.K.C., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Pfister S.M., Reyes-Múgica M., Chan J.K., Hasle H., Lazar A.J., Rossi S., Ferrari A., Jarzembowski J.A., Pritchard-Jones K., Hill D.A., et al. A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discov. 2022;12:331–355. doi: 10.1158/2159-8290.CD-21-1094. - DOI - PMC - PubMed
    1. Arber D.A., Orazi A., Hasserjian R.P., Borowitz M.J., Calvo K.R., Kvasnicka H.-M., Wang S.A., Bagg A., Barbui T., Branford S., et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–1228. doi: 10.1182/blood.2022015850. - DOI - PMC - PubMed
    1. Bolouri H., Farrar J.E., Triche T., Jr., Ries R.E., Lim E.L., Alonzo T.A., Ma Y., Moore R., Mungall A.J., Marra M.A., et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 2018;24:103–112. doi: 10.1038/nm.4439. - DOI - PMC - PubMed

LinkOut - more resources